SEOUL, May 30 (Reuters) - South Korea's Samsung Bioepis said
on Monday its biosimilar of Johnson & Johnson's
blockbuster rheumatoid arthritis drug Remicade has received
final approval from European regulators, paving the way for its
second product launch in Europe.
Read more
No comments:
Post a Comment